Frank Lammert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frank Lammert has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Siegfried Matern
Department of Medicine III, University Hospital Aachen, Aachen University, Aachen, Germany
7 shared publicationsHermann E. Wasmuth
Department of Medicine III, University Hospital Aachen, Aachen University, Aachen, Germany
5 shared publicationsAndreas Geier
Department of Medicine III, University Hospital Aachen, Aachen University, Aachen, Germany
3 shared publicationsCarsten Gartung
Department of Medicine III, University Hospital Aachen, Aachen University, Aachen, Germany
3 shared publicationsChristoph G. Dietrich
Department of Medicine III, University Hospital Aachen, Aachen University, Aachen, Germany
3 shared publicationsJohann Lorenzen
Institute of Pathology, University Hospital Aachen, Aachen University, Aachen, Germany
3 shared publications
Latest Publications
- Open Access
- 13 August 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 40 (2) , 327-334
Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C†
The response to antiviral therapy for chronic hepatitis C virus (HCV) is complex and is determined by both environmental and genetic factors. Recently, interacting gene polymorphisms of the chemokine RANTES have been shown to affect HIV disease progression. Our aim was to assess if these RANTES variants are associated with response to anti-HCV therapy. Three linked RANTES single nucleotide polymorphisms (403 G/A, Int1.1 T/C, and 3′ 222 T/C) were determined in 297 Caucasian patients who were treated for chronic HCV infection and 152 control subjects. Characteristic nucleotide combinations on single chromosomes (haplotypes) were reconstructed and tested for disease association. Four common RANTES haplotypes (prevalence 73%) were identified in patients and controls. There was a strong association of RANTES haplotype distribution with outcome of antiviral combination therapy (P = .007). Specifically, RANTES haplotypes carrying Int1.1 C and 3′ 222 C alleles were more frequent in nonresponders than in patients with a sustained response to antiviral therapy (odds ratio 1.9, P = .01). The influence of these RANTES haplotypes on the outcome of therapy was more pronounced in patients infected with HCV genotypes 1 and 4 (odds ratio 2.3, P = .02). Because RANTES haplotypes carrying Int1.1 C are known to down-regulate RANTES transcriptional activity in vitro, the haplotype analysis fits the hypothesis of a diminished T helper 1 lymphocyte response in patients with a negative response to antiviral therapy. In conclusion, RANTES haplotypes might contribute to the polygenic interaction between HCV and the host immune system and could help to risk stratify patients prior to antiviral therapy. (Hepatology 2004;40:327-334.)
- 13 August 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 40 (2) , 327-334
Open AccessHaplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C†
The response to antiviral therapy for chronic hepatitis C virus (HCV) is complex and is determined by both environmental and genetic factors. Recently, interacting gene polymorphisms of the chemokine RANTES have been shown to affect HIV disease progression. Our aim was to assess if these RANTES variants are associated with response to anti-HCV therapy. Three linked RANTES single nucleotide polymorphisms (403 G/A, Int1.1 T/C, and 3′ 222 T/C) were determined in 297 Caucasian patients who were treated for chronic HCV infection and 152 control subjects. Characteristic nucleotide combinations on single chromosomes (haplotypes) were reconstructed and tested for disease association. Four common RANTES haplotypes (prevalence 73%) were identified in patients and controls. There was a strong association of RANTES haplotype distribution with outcome of antiviral combination therapy (P = .007). Specifically, RANTES haplotypes carrying Int1.1 C and 3′ 222 C alleles were more frequent in nonresponders than in patients with a sustained response to antiviral therapy (odds ratio 1.9, P = .01). The influence of these RANTES haplotypes on the outcome of therapy was more pronounced in patients infected with HCV genotypes 1 and 4 (odds ratio 2.3, P = .02). Because RANTES haplotypes carrying Int1.1 C are known to down-regulate RANTES transcriptional activity in vitro, the haplotype analysis fits the hypothesis of a diminished T helper 1 lymphocyte response in patients with a negative response to antiviral therapy. In conclusion, RANTES haplotypes might contribute to the polygenic interaction between HCV and the host immune system and could help to risk stratify patients prior to antiviral therapy. (Hepatology 2004;40:327-334.)
- 5 July 2004
- Published by Wiley in Liver International
- Vol. 24 (4) , 285-294
Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C
Abstract: Background: Chronic hepatitis C is frequently associated with increased hepatic iron stores. It remains controversial whether heterozygous mutations of hemochromatosis genes affect fibrosis progression. Therefore our aim was to assess associations between HFE mutations and hepatic inflammation and stage of fibrosis in German hepatitis C patients.Methods: Liver biopsies from 166 patients were scored for inflammatory activity (A0–4) and hepatic fibrosis (F0–4). Gene mutations were determined by LightCycler, restriction fragment length polymorphism analysis, or direct sequencing.Results: The frequencies of common HFE mutations C282Y and H63D are 4.2% and 21.3%, whereas the recently described S65C substitution and the Y250X mutation in the transferrin receptor 2 gene are very rare. In regression analysis, heterozygous carriers of C282Y or H63D mutations display significantly (PPPConclusions: Common heterozygous hemochromatosis mutations are associated with higher grades of inflammation and more severe hepatic fibrosis. Our findings support a role of HFE mutations as primary risk factors for fibrogenesis and disease progression in chronic hepatitis C.
- 5 July 2004
- Published by Wiley in Liver International
- Vol. 24 (4) , 285-294
Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C
Abstract: Background: Chronic hepatitis C is frequently associated with increased hepatic iron stores. It remains controversial whether heterozygous mutations of hemochromatosis genes affect fibrosis progression. Therefore our aim was to assess associations between HFE mutations and hepatic inflammation and stage of fibrosis in German hepatitis C patients.Methods: Liver biopsies from 166 patients were scored for inflammatory activity (A0–4) and hepatic fibrosis (F0–4). Gene mutations were determined by LightCycler, restriction fragment length polymorphism analysis, or direct sequencing.Results: The frequencies of common HFE mutations C282Y and H63D are 4.2% and 21.3%, whereas the recently described S65C substitution and the Y250X mutation in the transferrin receptor 2 gene are very rare. In regression analysis, heterozygous carriers of C282Y or H63D mutations display significantly (PPPConclusions: Common heterozygous hemochromatosis mutations are associated with higher grades of inflammation and more severe hepatic fibrosis. Our findings support a role of HFE mutations as primary risk factors for fibrogenesis and disease progression in chronic hepatitis C.
- Open Access
- 1 July 2004
- Published by Elsevier in Annals of Hepatology
- Vol. 3 (3) , 118-120
Enlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma
- 1 July 2004
- Published by Elsevier in Annals of Hepatology
- Vol. 3 (3) , 118-120
Open AccessEnlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma
- 1 July 2004
- Published by Springer Nature in Der Gynäkologe
- Vol. 37 (7) , 590
Lebererkrankungen in der Schwangerschaft
- 1 July 2004
- Published by Springer Nature in Der Gynäkologe
- Vol. 37 (7) , 590
Lebererkrankungen in der Schwangerschaft
- 1 May 2004
- Published by Springer Nature in Der Gynäkologe
- Vol. 37 (5) , 418-426
Lebererkrankungen in der Schwangerschaft
- 1 May 2004
- Published by Springer Nature in Der Gynäkologe
- Vol. 37 (5) , 418-426
Lebererkrankungen in der Schwangerschaft
- Open Access
- 27 February 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 39 (3) , 604-607
From genotypes to haplotypes in hepatobiliary diseases: One plus one equals (sometimes) more than two
- 27 February 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 39 (3) , 604-607
Open AccessFrom genotypes to haplotypes in hepatobiliary diseases: One plus one equals (sometimes) more than two
- Open Access
- 13 February 2004
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 4 (1) , 4
The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C
Non-organ-specific autoantibodies are found in a considerable number of anti-HCV positive patients. Previous studies investigated the clinical relevance of these antibodies in patients treated with interferon monotherapy, but not combination therapies. Anti-nuclear, anti-smooth muscle, anti-mitochondrial, anti-neutrophil-cytoplasmatic and anti-liver/kidney microsomal antibodies were determined in 78 consecutive anti-HCV positive patients by indirect immunofluorescence. The presence of these antibodies was related to demographic variables and to the outcome of antiviral combination therapy with interferon-α and ribavirin in 65 patients. In our study, positivity for autoantibodies was associated with higher alanine aminotransferase levels and higher mean values for HCV-RNA (p < 0.01). Furthermore, negativity for non-organ-specific autoantibodies was associated with a favourable treatment outcome of combination therapy with at least one negative RT-PCR for HCV-RNA during treatment (OR 4.65, 95% CI 1.31 to 16.48, p = 0.02). ANA and SMA staining patterns and titers were not correlated to treatment response. With multiple logistic regression analysis, positivity for autoantibodies and HCV genotype were independently associated with outcome of antiviral combination therapy (p = 0.02). The absence of non-organ-specific autoantibodies might indicate a significantly higher chance for viral clearance in response to combination therapy for chronic hepatitis C infection. Therefore, despite of an overall higher treatment response, the addition of the immunomodulatory drug ribavirin could accentuate immunological differences that affect treatment outcome and might have been less obvious in earlier studies analysing interferon monotherapy.
- 13 February 2004
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 4 (1) , 4
Open AccessThe presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C
Non-organ-specific autoantibodies are found in a considerable number of anti-HCV positive patients. Previous studies investigated the clinical relevance of these antibodies in patients treated with interferon monotherapy, but not combination therapies. Anti-nuclear, anti-smooth muscle, anti-mitochondrial, anti-neutrophil-cytoplasmatic and anti-liver/kidney microsomal antibodies were determined in 78 consecutive anti-HCV positive patients by indirect immunofluorescence. The presence of these antibodies was related to demographic variables and to the outcome of antiviral combination therapy with interferon-α and ribavirin in 65 patients. In our study, positivity for autoantibodies was associated with higher alanine aminotransferase levels and higher mean values for HCV-RNA (p < 0.01). Furthermore, negativity for non-organ-specific autoantibodies was associated with a favourable treatment outcome of combination therapy with at least one negative RT-PCR for HCV-RNA during treatment (OR 4.65, 95% CI 1.31 to 16.48, p = 0.02). ANA and SMA staining patterns and titers were not correlated to treatment response. With multiple logistic regression analysis, positivity for autoantibodies and HCV genotype were independently associated with outcome of antiviral combination therapy (p = 0.02). The absence of non-organ-specific autoantibodies might indicate a significantly higher chance for viral clearance in response to combination therapy for chronic hepatitis C infection. Therefore, despite of an overall higher treatment response, the addition of the immunomodulatory drug ribavirin could accentuate immunological differences that affect treatment outcome and might have been less obvious in earlier studies analysing interferon monotherapy.
- 1 December 2003
- Published by Springer Nature in Medizinische Klinik
- Vol. 98 (12) , 754-762
Genetische Risikofaktoren der Fibrogenese bei chronischen Lebererkrankungen*
- 1 December 2003
- Published by Springer Nature in Medizinische Klinik
- Vol. 98 (12) , 754-762
Genetische Risikofaktoren der Fibrogenese bei chronischen Lebererkrankungen*
- 1 April 2003
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 6 (2) , 123-132
Intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (or obstetric cholestasis) is a liver disorder that occurs in late pregnancy. Despite the potential adverse maternal and fetal/neonatal outcomes, cholestasis of pregnancy is often neglected and treated expectantly. More research is needed to improve the molecular and genetic understanding of the disease and to define a safe and effective medical treatment that improves clinical outcome. Ursodeoxycholic acid is considered to be a safe treatment option in the third trimester, but further randomized controlled trials are needed before ursodeoxycholic acid treatment can be generally recommended. Ursodeoxycholic acid is preferentially administered to patients with severe cholestasis (onset before week 33 or serum bile acid levels > 70 mmol/L) or to patients with a history of sudden fetal death, while maintaining close obstetric and regular biochemical surveillance (transaminases, bilirubin, and bile acid levels). Ursodeoxycholic acid can decrease pruritus and ameliorate liver tests, but effects on obstetric complications are ambiguous. S-Adenosylmethionine, dexamethasone, and cholestyramine can provide some relief of itching. Because none of these drugs have been shown to be harmful to mother or fetus, the individual woman and her clinician may decide whether to try one of the treatments described.
- 1 April 2003
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 6 (2) , 123-132
Intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (or obstetric cholestasis) is a liver disorder that occurs in late pregnancy. Despite the potential adverse maternal and fetal/neonatal outcomes, cholestasis of pregnancy is often neglected and treated expectantly. More research is needed to improve the molecular and genetic understanding of the disease and to define a safe and effective medical treatment that improves clinical outcome. Ursodeoxycholic acid is considered to be a safe treatment option in the third trimester, but further randomized controlled trials are needed before ursodeoxycholic acid treatment can be generally recommended. Ursodeoxycholic acid is preferentially administered to patients with severe cholestasis (onset before week 33 or serum bile acid levels > 70 mmol/L) or to patients with a history of sudden fetal death, while maintaining close obstetric and regular biochemical surveillance (transaminases, bilirubin, and bile acid levels). Ursodeoxycholic acid can decrease pruritus and ameliorate liver tests, but effects on obstetric complications are ambiguous. S-Adenosylmethionine, dexamethasone, and cholestyramine can provide some relief of itching. Because none of these drugs have been shown to be harmful to mother or fetus, the individual woman and her clinician may decide whether to try one of the treatments described.
- Open Access
- 13 February 2003
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 33 (2) , 155-160
Mouse models for genetic dissection of polygenic gastrointestinal diseases
Many diseases with a major public health impact are the result of complex interactions between environmental factors and multiple genes. In the past decade, methods for genome analysis, in particular quantitative trait locus (QTL) analysis in animal models, were developed to identify and localize the genes responsible for multifactorial (polygenic) diseases; QTL analysis is based on experimental crosses between inbred strains with high and low genetic susceptibility. Recently the genes underlying several QTLs could be cloned successfully. Here we describe the impact of these genomic approaches in mice on our understanding of the multifactorial genetics of three gastrointestinal diseases related to metabolism (cholesterol cholelithiasis), development (gastroschisis), and colorectal cancer. The examples demonstrate how mouse models continue to be an invaluable tool in unravelling complex pathomechanisms and unlocking our understanding of human diseases.
- 13 February 2003
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 33 (2) , 155-160
Open AccessMouse models for genetic dissection of polygenic gastrointestinal diseases
Many diseases with a major public health impact are the result of complex interactions between environmental factors and multiple genes. In the past decade, methods for genome analysis, in particular quantitative trait locus (QTL) analysis in animal models, were developed to identify and localize the genes responsible for multifactorial (polygenic) diseases; QTL analysis is based on experimental crosses between inbred strains with high and low genetic susceptibility. Recently the genes underlying several QTLs could be cloned successfully. Here we describe the impact of these genomic approaches in mice on our understanding of the multifactorial genetics of three gastrointestinal diseases related to metabolism (cholesterol cholelithiasis), development (gastroschisis), and colorectal cancer. The examples demonstrate how mouse models continue to be an invaluable tool in unravelling complex pathomechanisms and unlocking our understanding of human diseases.